For the last couple of months, Fibrocell Science, Inc. (OTC:FCSC) has been slowly but surely going down the charts. What is more, there seem to be no technical indicators which could suggest a complete reversal of the trend any time soon.
If you take a closer look at the data outlining the historical market performance of FCSC stock for the last six months or so, you will easily notice that FCSC has undergone no drastic changes. Nor has it been volatile enough to urge traders to speculate on the company’s share value. Yet, FCSC has been going straight down for quite a while now.
When we last covered FCSC in early-December, the company had just announced a couple of presentations scheduled to take place on two different forums in San Francisco and New York City, respectively. Another similar announcement came up on Jan. 4 regarding a presentation at a medical forum to be held in San Francisco on Jan. 9-12.
No other news have since seen the light of day, except for a 424B3 prospectus form. Filed with the SEC yesterday, the document served to inform investors about the resale of 3+ million common shares underlying warrants issued in a private placement.
FCSC’s latest quarterly reports indicate that the company has sufficient cash reserves to ensure optimal business operations for a few more quarters. However, the fact that the company has been incurring an average quarterly loss of $4.2 million for the last four quarters has not gone unnoticed, which is why FCSC stock has been unable to achieve a breakthrough.
